In addition to Gabriel's post I would like to say that the cancer treatment pharmaceutical companies seem to be greatly deveeloping and emerging into the market. The need to develop treatments for cancer is always being perfectioned and researched by many comapanies, as it is an illness that takes away many lives.
Spectrum Pharmaceuticals is another company that specializes in oncology and other drugs that are specific to illnesses that are difficult to treat; such as Schizophrenia or Attention Deficit Hyperactivity Disorder. It is ranked 23rd on the survey conducted by Deloitte of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. The lastest drug that was brough out by Spectrum was Fusilev (Levoleucovorin) for injection, in April 2011. Fusilev is designed for the treatment in Patients with Advanced Metastatic Colorectal Cancer.
Just like Gabriel said, I believe that the fact that so many of these companies are emerging will be a positive one for the future. They research and develop drugs to help treat and cure many illnesses that are difficult or fatal. Therefore, the fact that they are gaining bigger places in the market place is favorable as they will be able to find more solutions for diseases that are still uncurable.
http://www.spectrumpharm.com/outlicense_Spectrum.html
http://investor.spectrumpharm.com/releasedetail.cfm?releaseid=530172
Maria Durá Ballester
This was really helpful when I was writing the entrepreneurship section of the final draft! Cancer research is such a new topic its good to know that new companies can emerge even in this day and age. Unfortunately the only reason they are able to emerge is because things like cancer still have no cure.
ReplyDeleteI spoke to my uncle the other day who owns his own small pharmaceutical company that has been very successful in Italy, and he informed me of the importance of developing new drugs as each new cure discovery leads to exponential growth for research in that field. Each one can help build on the other and future research.
ReplyDelete